257 related articles for article (PubMed ID: 31023244)
1. Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials.
Connock M; Armoiry X; Tsertsvadze A; Melendez-Torres GJ; Royle P; Andronis L; Clarke A
BMC Cancer; 2019 Apr; 19(1):392. PubMed ID: 31023244
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis.
Armoiry X; Tsertsvadze A; Connock M; Royle P; Melendez-Torres GJ; Souquet PJ; Clarke A
PLoS One; 2018; 13(7):e0199575. PubMed ID: 30044785
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis.
Créquit P; Chaimani A; Yavchitz A; Attiche N; Cadranel J; Trinquart L; Ravaud P
BMC Med; 2017 Oct; 15(1):193. PubMed ID: 29082855
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
9. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
Vickers AD; Winfree KB; Cuyun Carter G; Kiiskinen U; Jen MH; Stull D; Kaye JA; Carbone DP
BMC Cancer; 2019 Apr; 19(1):353. PubMed ID: 30987609
[TBL] [Abstract][Full Text] [Related]
10. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
Goss GD; Spaans JN
Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
12. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Melosky B; Juergens R; Hirsh V; McLeod D; Leighl N; Tsao MS; Card PB; Chu Q
Oncologist; 2020 Jan; 25(1):64-77. PubMed ID: 31138727
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL
Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866
[TBL] [Abstract][Full Text] [Related]
15. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
18. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L
PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047
[TBL] [Abstract][Full Text] [Related]
19. EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis.
Liu M; Xiao K; Yang L
Int Immunopharmacol; 2023 Jun; 119():110001. PubMed ID: 37075672
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
